Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.73 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.73 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.57 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | PTPRC | P08575 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087296 | 0.86 | MAOB (0.76) | MAOBPARP15PARP14PARP10MAOA | |
| SCHEMBL1444784 | 0.86 | MAOB (0.75) | MAOBPARP15PARP14PARP10LPAR1 | |
| SCHEMBL1444069 | 0.85 | MAOB (0.74) | MAOBPARP15PARP14PARP10LPAR1 | |
| SCHEMBL20883219 | 0.84 | PARP10 (1.00) | MAOBPARP15PARP14PARP10LPAR1 | |
| SCHEMBL2087291 | 0.84 | MAOB (0.72) | MAOBPARP15PARP14PARP10MAOA | |
| SCHEMBL2089746 | 0.83 | MAOB (1.00) | MAOBMAOAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2087289 | 0.83 | MAOB (0.70) | MAOBMAOAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL8052915 | 0.83 | MAOB (0.72) | MAOBMAOAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2088042 | 0.82 | MAOB (0.79) | MAOBPARP15PARP14PARP10MAOA | |
| SCHEMBL14364629 | 0.82 | MAOB (0.69) | MAOBPARP15PARP14PARP10LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109528716-B | Application of chalcone compound containing carboxymethyl rhodanine structure | 延边大学 | 2021-02-02 | — | — | CN | disclosed |
| US-9181265-B2 | Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2015-11-10 | — | — | US | disclosed |
| US-9181265-B2 | Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2015-11-10 | — | — | US | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-8604083-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130289030-A1 | NOVEL PHENAZINE DERIVATIVES AND THEIR USES | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289030-A1 | NOVEL PHENAZINE DERIVATIVES AND THEIR USES | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2013-10-31 | — | — | US | disclosed |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-24 | — | — | US | disclosed |
| EP-1461323-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8552062-B2 | Methods for the treatment of metabolic disorders such as diabetes | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0288297-A2 | Optically active benzene derivatives and process for preparation thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885PARP15 3746/4885PARP14 3673/4885 |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885PARP15 3746/4885PARP14 3673/4885 |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | MAOB 589/4885PARP15 3746/4885PARP14 3673/4885 |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885PARP15 3746/4885PARP14 3673/4885 |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885PARP15 3746/4885PARP14 3673/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885PARP15 3746/4885PARP14 3673/4885 |
| US-20130289030-A1 | NOVEL PHENAZINE DERIVATIVES AND THEIR USES | VEGFA, KDR, FLT4 | MAOB 1741/4885PARP15 659/4885PARP14 2462/4885 |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885PARP15 3746/4885PARP14 3673/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885PARP15 3746/4885PARP14 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.